In a recent study, published Monday in the Archives of Internal Medicine, it has been found that all those drugs that are approved by the Health Canada on a priority basis are more likely to cause serious safety problems to the patients later, whereas on the other hand, drugs that are deeply reviewed before releasing into the market have very lower chances for the same.

The study discovered, around 35% of new drugs that are approved by the federal regulator’s priority review system later are either recalled from the market else they are immediately banned with some staid safety warnings.

As far as other drugs are concerned that are analyzed and approved following the standard process, there are only 20% which poses danger later some time.

The standard process that Health Canada follows for reviewing drugs includes testing for 300 days, whereas in a priority review it is done for just 120 days.

As said by York University professor Joel Lexchin, who is the author of this study, “The length of time matters because it appears they missed things. The issue is, can you do as good a job evaluating that material in 180 days as you would in 300 days? Or are you going to miss things?”